Politicians and journalists spent a pleasantly short week shaking their metaphorical fists at Pfizer CEO Ian Read. Their duty fulfilled, they could knock off early for Thanksgiving.

Mr. Readâ€™s sin, however, was more apparent than real. To dodge the much higher U.S. corporate tax rate on its prodigious overseas earnings, the pharmaceutical giant restyled its anticipated takeover of an Irish company as a takeover of Pfizer by the Irish company. To a writer for the New Yorker magazine, echoing a wide consensus, this was a...